Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12

Blood

Volumn 93, Issue 5, 1999, Pages 1612-1621

  Yao, Lei ^a   Sgadari, Cecilia ^b   Furuke, Keizo ^b   Bloom, Eda T ^b   Teruya Feldstein, Julie ^b   Tosato, Giovanna ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BASIC FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GANGLIOTETRAOSYLCERAMIDE; GRANZYME B; INTERLEUKIN 12; PERFORIN; RECOMBINANT INTERLEUKIN 12; RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; IMMUNOHISTOCHEMISTRY; MOUSE; NATURAL KILLER CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033104852     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1612.405a13_1612_1621     Document Type: Article

References (52)

1. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827, 1989
2. Wolf S, Temple P, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick R, Kelleher K, Herrmann S, Clark S, Azzoni L, Chan S, Trinchieri G, Perussia B: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074, 1991
3. D'Andrea A, Rengaraju M, Valiante N, Chehimi J, Kubin M, Aste M, Chan S, Kobayashi M, Young D, Nickbarg E: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176:1387, 1992
4. Gately M, Warner R, Honasoge S, Carvajal D, Faherty D, Connaughton S, Anderson T, Sarimento U, Hubbard B: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 6:157, 1994
5. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH, Ritz J: Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779, 1992
6. Manetti R, Parronchi P, Giudizi M, Piccini M, Maggi E, Trinchieri G, Romagnani S: Natural killer cell stimulatory (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 177:1199, 1993
7. + T cells through IL-12 produced by Listeria induced macrophages. Science 260:547, 1993
8. Heinzel F, Schoenhaut D, Rerko R, Rosser L, Gately M: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177:1505, 1993
9. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90:3725, 1993
10. Wynn T, Jankovic D, Heiny S, Cheever A, Sher A: Endogenous IL-12 regulates granuloma formation induced by eggs of schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 179:1551, 1994
11. Brunda M, Luistro L, Warrier R, Wright R, Hubbard B, Murphy M, Wolf S, Gately M: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223, 1993
12. Tahara H, Zeh Hr, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182, 1994
13. Nastala C, HD E, McKinney T, Tahara H, Nalesnik M, Brunda M, Gately M, Wolf S, Schreiber R, Storkus W, Lotze M: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697, 1994
14. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581, 1995
15. Kerbel R, Hawley R: Interleukin 12: Newest member of the antiangiogenesis club. J Natl Cancer Inst 87:557, 1995
16. Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877, 1996
17. Angiolillo A, Sgadari C, Taub D, Liao F, Farber J, Maheshwari S, Kleinman H, Reaman G, Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155, 1995
18. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61:246, 1997
19. Luster A, Greenberg S, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219, 1995
20. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark LI, Baggiolini M, Moser B: Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963, 1996
21. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B: The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 28:961, 1998
22. Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA, Hedrick J, Zlotnik A: The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 95:8205, 1998
23. Suttles J, Schwarting GA, Stout RD: Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J Immunol 136:1586, 1986
24. Solomon FR, Higgins TJ: A monoclonal antibody with reactivity to asialo GM1 and murine natural killer cells. Mol Immunol 24:57, 1987
25. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67:519, 1992
26. Snapper CM, Yamaguchi H, Moorman MA, Mond JJ: An in vitro model for T cell-independent induction of humoral immunity. A requirement for NK cells. J Immunol 152:4884, 1994
27. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya FJ, Tosato G: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791, 1996
28. Riser BL, Laybourn KA, Varani J: Treatment of mice with anti-asialo-GM1 antibody or poly-I:C: effects on metastasis dissociable from modulation of macrophage antitumor activity. Nat Immun Cell Growth Regul 7:305, 1988
29. Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T: A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 10:175, 1980
30. + lymphokine-activated killer subset. J Immunol 150:17, 1993
31. Okada K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herberman RB, Whiteside TL: Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res 56:1599, 1996
32. Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW: Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134:2783, 1985
33. Koo GC, Dumont FJ, Tutt M, Hackett JJ, Kumar V: The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol 137:3742, 1986
34. Luster A, Leder P: IP-10, a -C-X-C-chemokine, elicits a potent thymus dependent antitumor response in vivo. J Exp Med 178:1057, 1993
35. Liao F, Rabin R, Yannelli J, Koniaris L, Vanguri P, Farber J: The human Mig chemokine: Biochemical and functional characterization. J Exp Med 182:1301, 1995
36. Peitsch MC, Tschopp J: Assembly of macromolecular pores by immune defense systems. Curr Opin Cell Biol 3:710, 1991
37. Kawasaki A, Shinkai Y, Kuwana Y, Furuya A, Iigo Y, Hanai N, Itoh S, Yagita H, Okumura K: Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells. Int Immunol 2:677, 1990
38. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89:2635, 1997
39. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Tosato T: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64:384, 1998
40. Allavena P, Paganin C, Martin PI, Peri G, Gaboli M, Dejana E, Marchisio PC, Mantovani A: Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med 173:439, 1991
41. Damle NK, Doyle LV: IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol 142:2660, 1989
42. Tosato G, Sgadari C, Taga K, Jones KD, Pike SE, Rosenberg A, Sechler JM, Magrath IT, Love LA, Bhatia K: Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood 83:776, 1994
43. Damle NK, Doyle LV, Bender JR, Bradley EC: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779, 1987
44. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS: Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 48:5528, 1988
45. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G: Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 233:231, 1997
46. Folkman J, D'Amore PA: Blood vessel formation: What is its molecular basis? Cell 87:1153, 1996
47. 3 antagonist promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157, 1994
48. Ferrara N, Heinsohn H, Walder CE, Bunting S, Thomas GR: The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 752:246, 1995
49. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032, 1996
50. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547, 1997
51. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856, 1995
52. Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15:180, 1997